What is Cyteir Therapeutics, Inc. (CYT)?

Cyteir Therapeutics, Inc. (CYT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CYT?

The current price of CYT is $3.02. Prices are updated in real time on Stocks360.

What is CYT's price-to-earnings (PE) ratio?

CYT's trailing twelve-month PE ratio is -2.42, based on current price and earnings per share data available on Stocks360.

What is CYT's market capitalization?

CYT's market capitalization is $108,714,262.00, placing it in the small-cap tier.

Cyteir Therapeutics, Inc. (CYT)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.02

Market Cap

$108.71M

PE (TTM)

-2.42

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.10

Day Range

$3.00 – $3.09

52-wk Range

$1.65 – $3.19

Avg Volume

N/A

Volume

1.01M

Cyteir Therapeutics, Inc. (CYT) is a publicly traded company in the Healthcare sector. Latest price: $3.02. Market cap $108.71M. Trailing PE -2.42. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

Mar 28, 2024

EPS $-0.25 vs est. $-0.20

Missed by $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.42×
P/S (TTM)	0.00×
P/B	0.73×
P/FCF (TTM)	-2.54×
EV / EBITDA	0.81×
EV / Sales	0.00×
Earnings Yield	-41.26%
Free Cash Flow Yield	-39.41%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$37.52M
Net Income (TTM)	-$44.86M
Free Cash Flow (TTM)	-$42.84M
Net Debt	-$146.23M
Working Capital	$143.89M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-26.35%
Return on Invested Capital	-32.37%